PD-1 immunotherapy in pancreatic cancer: current status
Journal of Pancreatology · 2019
DOI: 10.1097/jp9.0000000000000010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pancreatology, 2019. Verfasst von Ning Pu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma is the known kind of tumor biologically featured as high malignant degree, lack of effective methods for diagnosis and treatment, which reflects its unpleasant prognosis. Recently, with the breakthrough of burgeoning therapeutic methods, the flush of dawn for pancreatic cancer nearly arrives. Nowadays, besides surgery, neoadjuvant chemoradiotherapy, tumor vaccine therapy, and immunotherapy all show their active situation and obtain certain clinical efficacy, but that is still limited to pancreatic cancer. However, the appearance and development of programmed cell death-1 (PD-1) immune checkpoint inhibitor may final improve survival of pancreatic cancer. This article aims to deeply understand the value of PD-1 immune checkpoint inhibitor in pancreatic cancer and validly provide the evidence for treatment by means of performing a systematic review on the current status in the fields of the mechanism and application of anti-PD-1 in pancreatic cancer, associations with surgery, PD-1-related side effects and prospections.
Zitieren
APA
Pu, N., Lou, W., & Yu, J. (2019). PD-1 immunotherapy in pancreatic cancer: current status. Journal of Pancreatology. https://doi.org/10.1097/jp9.0000000000000010
Vancouver
Pu N, Lou W, Yu J. PD-1 immunotherapy in pancreatic cancer: current status. Journal of Pancreatology. 2019. doi:10.1097/jp9.0000000000000010
BibTeX
@article{Pu2019,
author = {Pu, Ning and Lou, Wenhui and Yu, Jun},
title = {PD-1 immunotherapy in pancreatic cancer: current status},
journal = {Journal of Pancreatology},
year = {2019},
doi = {10.1097/jp9.0000000000000010}
}
EUVIMED